Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report
Atezolizumab is an immune checkpoint inhibitor that is a key drug in non-small-cell lung cancer treatment. However, it can cause immune-related adverse events, including liver injury. Several patterns of liver injury associated with immune checkpoint inhibitor therapy have been reported; however, no...
Main Authors: | Shinji Nabeshima, Masahiro Yamasaki, Naoko Matsumoto, Shintaro Takaki, Yumi Nishi, Kazuma Kawamoto, Masaya Taniwaki, Nobuyuki Ohashi, Noboru Hattori |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Cancer Treatment and Research Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294220301052 |
Similar Items
-
Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report
by: Daisuke Jingu, et al.
Published: (2024-03-01) -
Difficulties in Diagnosing Isolated IgG4-associated Sclerosing Cholangitis
by: Gábor Zsóri, et al.
Published: (2019-01-01) -
Overlap Syndrome with Autoimmune Hepatitis and Primary Sclerosing Cholangitis
by: Jeremy S. Nayagam, et al.
Published: (2019-05-01) -
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics
by: Ji-Won Park, et al.
Published: (2022-05-01) -
Secondary sclerosing cholangitis in critically ill patients: current perspectives
by: Gudnason HO, et al.
Published: (2017-06-01)